BLUEPRINT MEDICINES CORP (BPMC) 45.65 -3.41 (-6.95%)
45.65 -3.41 (-6.95%)
US09627Y1091 - Common Stock - After market: 45.65 0 (0%)
BLUEPRINT MEDICINES CORP45.65
NASDAQ:BPMC (2/3/2023, 7:28:23 PM)-3.41 (-6.95%)
| GICS Sector | Health Care | ||
| GICS Industry | Biotechnology | ||
| Valuation | Growth | ||
| Profitability | Health | ||
| Dividend | |||
| Earnings (Last) | 11-01 2022-11-01/bmo | Earnings (Next) | 02-14 2023-02-14/amc |
| Ins Owners | 1.29% | Inst Owners | 104.52% |
| Market Cap | 2.73B | Shares | 59.83M |
| PE | N/A | Fwd PE | N/A |
| Dividend Yield | N/A | Analysts | 78.4 |
| IPO | 04-30 2015-04-30 | ||
Stock Screener Links
Nasdaq Stock Screener
Find more stocks on Nasdaq
USA Stock Screener
Find more stocks on the USA
GICS Sector Stock Screener
Find competitors from the same sector on the USA
GICS Industry Stock Screener
Find competitors from the same industry on the USA
Technical Stock Screener
Find stocks with similar TA and Setup ratings on the USA
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Growth Stock Screener
Find more growth stocks the USA
Best Technical Competitors Stock Screener
Find the competitors with the best technical ratings on the USA
Best Technical Setups Competitors Stock Screener
Find the competitors with the best technical and setup ratings on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA
Best Analyst Rating Competitors Stock Screener
Find the competitors with the best analyst ratings on the USA
Company Profile
Blueprint Medicines Corp. is a precision therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 602 full-time employees. The company went IPO on 2015-04-30. The firm delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib) to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include BLU-263 (KIT), AYVAKIT (avapritinib) (PDGFRA), BLU-701 (EGFR), BLU-945 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2) and BLU-852 (MAP4K1). The company is developing and commercializing avapritinib for the treatment of advanced SM, and developing avapritinib for the treatment of non-advanced SM. The firm is developing BLU-263, an investigational, orally available KIT inhibitor, for the treatment of non-advanced SM and other mast cell disorders.
Company Info
BLUEPRINT MEDICINES CORP
45 Sidney Street
Cambridge MASSACHUSETTS 02139
P: 16173747580.0
CEO: Jeffrey W. Albers
Employees: 602
Website: https://www.blueprintmedicines.com/
BPMC News
2 days ago - Blueprint Medicines CorporationBlueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present detailed results from the registrational PIONEER trial of...
13 days ago - Blueprint Medicines CorporationBlueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's...
a month ago - Blueprint Medicines CorporationBlueprint Medicines Appoints John Tsai, M.D. to its Board of Directors/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of John Tsai, M.D., to its board of directors. Dr. Tsai, who was...
a month ago - Blueprint Medicines CorporationBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...
2 months ago - Seeking AlphaCOGT stock initiated Buy at Needham citing a better profile for cancer drug (NASDAQ:COGT)Needham issued a Buy rating on Cogent Biosciences (COGT) on Wednesday, citing better prospects for its systemic mastocytosis candidate bezuclastinib. Read the full story here.
2 months ago - Seeking AlphaBPMC stock initiated Buy at Needham on sales prospects for cancer therapy (NASDAQ:BPMC)Needham launched its coverage on Blueprint Medicines Corporation (BPMC) on Wednesday with a Buy recommendation, citing sales potential of its cancer medication Ayvakit. Read full story here.
BPMC Twits
Here you can normally see the latest stock twits on BPMC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
